Sheraton Steamboat Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2001
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
The Molecular Basis of Neurodegenerative Disease (E1)
Organizer(s) Sangram S. Sisodia, Huda Y. Zoghbi, Paul F. Worley and Donald L. Price
March 29—April 3, 2001
Sheraton Steamboat Resort • Steamboat Springs, Colorado USA
Abstract Deadline: Nov 29, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 29, 2001
Sponsored in part by the Director's Sponsor Fund
Summary of Meeting:
The neurodegenerative disorders, a heterogeneous group of chronic progressive diseases, arise via complex etiologies. Fortunately, the discovery of pathogenic gene mutations that cause familial, autosomal dominant forms of several of these disorders have offered extraordinary opportunities to clarify the relationship of genetic lesions to the pathogenesis of these puzzling illnesses. Indeed, cell culture and transgenic animal models have been developed to address the cellular and molecular consequences of expressing mutant genes that cause familial forms of several disorders, including Alzheimer’s disease, prion diseases, trinucleotide expansion diseases and amytrophic lateral sclerosis. Despite these advances, the biochemical, physiological and clinical consequences of expressing mutant proteins in vivo and the underlying molecular bases for selective vulnerability of specific subsets of neurons in each of these disorders is poorly understood. Sadly, neither treatments, nor effective therapies have been developed for these devastating illnesses. Our program is intended to develop a conceptual framework that addresses these critical issues. The speakers will provide a synthesis of diverse areas that are highly pertinent to the topic, including brain development, synaptic plasticity, neurodegeneration, genetics, and models of neurodegenerative diseases. Finally, investigators will discuss the potential of neuroprotective and regenerative strategies for neurodegenerative disorders.
View Scholarships/Awards
The neurodegenerative disorders, a heterogeneous group of chronic progressive diseases, arise via complex etiologies. Fortunately, the discovery of pathogenic gene mutations that cause familial, autosomal dominant forms of several of these disorders have offered extraordinary opportunities to clarify the relationship of genetic lesions to the pathogenesis of these puzzling illnesses. Indeed, cell culture and transgenic animal models have been developed to address the cellular and molecular consequences of expressing mutant genes that cause familial forms of several disorders, including Alzheimer’s disease, prion diseases, trinucleotide expansion diseases and amytrophic lateral sclerosis. Despite these advances, the biochemical, physiological and clinical consequences of expressing mutant proteins in vivo and the underlying molecular bases for selective vulnerability of specific subsets of neurons in each of these disorders is poorly understood. Sadly, neither treatments, nor effective therapies have been developed for these devastating illnesses. Our program is intended to develop a conceptual framework that addresses these critical issues. The speakers will provide a synthesis of diverse areas that are highly pertinent to the topic, including brain development, synaptic plasticity, neurodegeneration, genetics, and models of neurodegenerative diseases. Finally, investigators will discuss the potential of neuroprotective and regenerative strategies for neurodegenerative disorders.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
THURSDAY, MARCH 29
FRIDAY, MARCH 30
SATURDAY, MARCH 31
SUNDAY, APRIL 1
MONDAY, APRIL 2
TUESDAY, APRIL 3
Conference Program Print | View meeting in 12 hr (am/pm) time
THURSDAY, MARCH 29
19:30—20:30
Opening Address
Donald L. Price,
Johns Hopkins University, USA
Overview of Neurodegenerative Diseases
Overview of Neurodegenerative Diseases
08:00—11:00
Neural Development
Hollis T. Cline,
The Scripps Research Institute, USA
Activity-regulated Mechanisms Controlling Brain Development
Activity-regulated Mechanisms Controlling Brain Development
Stephen T. Warren,
Emory University School of Medicine, USA
The Molecular Basis of Fragile X Syndrome
The Molecular Basis of Fragile X Syndrome
*
Judith Melki,
INSERM, France
Degenerative Process in Spinal Muscular Atrophy
Degenerative Process in Spinal Muscular Atrophy
Joachim Herz,
University of Texas Southwestern Medical Center, USA
Roles of Neuronal Apolipoprotein E Receptors in Brain Development and Neurodegeneration
Roles of Neuronal Apolipoprotein E Receptors in Brain Development and Neurodegeneration
20:00—22:00
Synaptic Interactions
*
Thomas C. Südhof,
Stanford School of Medicine, USA
Molecular Mechansims of Presynaptic Plasticity
Molecular Mechansims of Presynaptic Plasticity
Paul F. Worley,
Johns Hopkins School of Medicine, USA
Activity-Dependent Synaptic Plasticity
Activity-Dependent Synaptic Plasticity
Roberto Malinow,
University of California, San Diego, USA
AMPA Receptor Trafficking During Synaptic Plasticity
AMPA Receptor Trafficking During Synaptic Plasticity
08:00—11:00
Mechanisms of Neurodegeneration
*
Michael E. Greenberg,
Harvard Medical School, USA
Signal Transduction Pathways that Prevent Neurodegeneration
Signal Transduction Pathways that Prevent Neurodegeneration
Dale E. Bredesen,
Buck Institute for Research on Aging, USA
An Alternative, Non-apoptotic Form of Programmed Cell Death
An Alternative, Non-apoptotic Form of Programmed Cell Death
Jeffrey H. Kordower,
Rush Presbyterian St. Lukes Medical College, USA
Lentiviral Delivery of GDNF in Nonhuman Primate Models of Parkinson's Disease
Lentiviral Delivery of GDNF in Nonhuman Primate Models of Parkinson's Disease
Mahlon Delong,
Emory University School of Medicine, USA
Pathophysiology of Parkinson's Disease
Pathophysiology of Parkinson's Disease
16:00—18:00
Poster Session 2: Mechanisms of Neurodegeneration/Genetics of Neurodegenerative Diseases
20:00—22:00
Genetics of Neurodegenerative Diseases
Kenneth H. Fischbeck,
National Institutes of Health, USA
Kennedy's Disease
Kennedy's Disease
*
Rudolph E. Tanzi,
Massachusetts General Hospital, USA
The Genetics of Alzheimer's Disease
The Genetics of Alzheimer's Disease
Short Talk(s) Chosen from Abstracts
08:00—11:00
Mutant Proteins in Neurodegenerative Diseases
Sangram S. Sisodia,
University of Chicago, USA
Molecular Mechanisms of Familial Alzheimer's Disease
Molecular Mechanisms of Familial Alzheimer's Disease
Huda Y. Zoghbi,
HHMI/Baylor College of Medicine, USA
Genetic Studies to Unravel the Pathogenesis of Spinocerebellar Ataxia Type 1
Genetic Studies to Unravel the Pathogenesis of Spinocerebellar Ataxia Type 1
Virginia M. Y. Lee,
University of Pennsylvania School of Medicine, USA
Pathobiology of Mutant Tau Proteins in Neurodegenerative Diseases
Pathobiology of Mutant Tau Proteins in Neurodegenerative Diseases
*
Jeffrey D. Rothstein,
Johns Hopkins University, USA
Amytrophic Lateral Sclerosis - Multiple Proteins Responsible for Motor Neuron Degeneration
Amytrophic Lateral Sclerosis - Multiple Proteins Responsible for Motor Neuron Degeneration
16:00—18:00
Poster Session 3: Mutant Proteins in Neurodegenerative Diseases/Animal Models/Molecular Mechanisms/Regeneration and Repair
20:00—22:00
Animal Models
Donald L. Price,
Johns Hopkins University, USA
The Value of Transgenic Models for Studies of Neurodegenerative Disease
The Value of Transgenic Models for Studies of Neurodegenerative Disease
*
Don W. Cleveland,
University of California, San Diego, USA
SOD1 Mutants, Neurofilaments and Lou Gehrig’s Disease
SOD1 Mutants, Neurofilaments and Lou Gehrig’s Disease
Harry T. Orr,
University of Minnesota, USA
The Molecular Basis of a Polyglutamine-Induced Neurodegenerative Disease, SCA1
The Molecular Basis of a Polyglutamine-Induced Neurodegenerative Disease, SCA1
08:00—11:00
Molecular Mechanisms
Patrick Tremblay,
University of California, San Francisco, USA
Transgenic Models to Study the Development of Prion Diseases
Transgenic Models to Study the Development of Prion Diseases
*
Ted M. Dawson,
Johns Hopkins University School of Medicine, USA
Molecular Mechanisms of Selective Vulnerability in Parkinson's Disease
Molecular Mechanisms of Selective Vulnerability in Parkinson's Disease
David R. Borchelt,
Johns Hopkins School of Medicine, USA
Transgenic Mouse Models of Polyglutamine Disorders
Transgenic Mouse Models of Polyglutamine Disorders
Mirella Gonzalez-Zulueta,
AGY Therapeutics, USA
Mechanistic Pathways of Neurological Disease Models Based on Gene Expression Analysis
Mechanistic Pathways of Neurological Disease Models Based on Gene Expression Analysis
16:00—18:00
Regeneration and Repair
Evan Snyder,
Sanford-Burnham Medical Research Institute, USA
Neural Stem Cells May be Ideally Suited for Gene Therapy and Cell Replacement in the Degenerating CNS
Neural Stem Cells May be Ideally Suited for Gene Therapy and Cell Replacement in the Degenerating CNS
Steven Goldman,
University of Rochester Medical Center, USA
Isolation and Induction of A Neural Progenitors of the Adult Human Brain
Isolation and Induction of A Neural Progenitors of the Adult Human Brain
*
Ronald D. McKay,
Lieber Institute for Brain Development, USA
From Stem Cells to Synapses
From Stem Cells to Synapses
*Session Chair †Invited, not yet responded.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
